Beam Therapeutics (BEAM) vs Maze Therapeutics (MAZE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Beam Therapeutics (BEAM) has outperformed Maze Therapeutics (MAZE) over the past year, losing 5.9% versus a loss of 13.5%. Beam Therapeutics is the larger company by market cap ($2.16 billion vs $1.72 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BEAM | MAZE |
|---|---|---|
| Share price | $20.90 | $31.37 |
| Market cap | $2.16B | $1.72B |
| 1-day change | -0.19% | -3.27% |
| YTD return | -24.60% | -24.28% |
| 1-year return | -5.90% | -13.49% |
| 5-year return | -73.44% | — |
| EPS (TTM) | $-0.87 | $-2.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $139.74M | — |
| Revenue growth (YoY) | +120.01% | — |
| Net income (latest FY) | $-79.99M | $-131.12M |
| Operating margin | -274.57% | — |
| Net margin | -57.24% | — |
| 52-week high | $38.26 | $53.65 |
| 52-week low | $20.44 | $21.95 |
| Distance from 52-week high | -45.37% | -41.53% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +138.52% | +99.11% |
| Average volume | 2.04M | 737.14K |
| Shares outstanding | 103.50M | 54.68M |
| Employees | 557 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Beam Therapeutics
BEAM stock →Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 557 employees
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
BEAM vs MAZE FAQ
Which is bigger, Beam Therapeutics or Maze Therapeutics?
Beam Therapeutics (BEAM) is larger, with a market capitalization of $2.16B compared with $1.72B for Maze Therapeutics (MAZE).
Which stock has performed better over the past year, BEAM or MAZE?
BEAM returned -5.90% over the past 12 months, compared with -13.49% for MAZE (price return, excluding dividends). Past performance does not predict future results.
Are Beam Therapeutics and Maze Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.